Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

EXPLAINED: Teva pharmaceutical indus | Rare Historical Photos

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022

Upgrades

Benzinga · Aug 5, 2022

12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga · Jul 27, 2022

Analyst Ratings for Teva Pharmaceutical Indus

Within the last quarter, Teva Pharmaceutical Indus (NYSE:TEVA) has observed the following analyst ratings:

Benzinga · Jun 14, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022

Upgrades

Benzinga · Jun 14, 2022

Golden Cross Appears Before Teva Pharmaceutical Indus Investors

If history is any guide, there may be good fortune ahead for shares of Teva Pharmaceutical Indus (NYSE:TEVA). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Benzinga · May 27, 2022

4 Analysts Have This to Say About Teva Pharmaceutical Indus

Over the past 3 months, 4 analysts have published their opinion on Teva Pharmaceutical Indus (NYSE:TEVA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga · May 12, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2022

Upgrades

Benzinga · May 4, 2022

Read news from The Economist, FT, and more,
with one subscription

Recap: Teva Pharmaceutical Q1 Earnings

Teva Pharmaceutical Indus (NYSE:TEVA) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · May 3, 2022

Teva Pharmaceutical Indus Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Teva Pharmaceutical Indus (NYSE:TEVA) reported Q4 sales of $4.10 billion. Earnings fell to a loss of $153.00 million, resulting in a 150.83% decrease from last quarter.

Benzinga · Feb 10, 2022

Teva Pharmaceutical: Q4 Earnings Insights

Teva Pharmaceutical Industries (NYSE:TEVA) reported its Q4 earnings results on Wednesday, February 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · Feb 9, 2022

Coverage From

Benzinga

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.